Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1179-1950

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis ; volume:80 ; number:14 ; day:2 ; month:9 ; year:2020 ; pages:1505 ; date:9.2020
Drugs ; 80, Heft 14 (2.9.2020), 1505, 9.2020

Creator: Blair, Hannah A.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s40265-020-01392-y

URN: urn:nbn:de:101:1-2020111418112609082836

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Blair, Hannah A.
SpringerLink (Online service)

Other Objects (12)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective

Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study

Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective

Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study

Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective

Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study

Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective

Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study

Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective

Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study

Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective

Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study

Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis

Related objects

Reset password